
---
title: '可能有新的抗病毒药物对抗COVID-19和疱疹'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202108/25/160546l5kousn8am8sotnl.jpg'
author: 科学网
comments: false
date: Wed, 25 Aug 2021 16:08:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202108/25/160546l5kousn8am8sotnl.jpg'
---

<div>   
<p style="line-height: 2em;"><span style="font-size: 24px; font-family: 黑体, SimHei;"><span style="font-size: 24px;">可能有新的抗病毒药物对抗</span><span style="font-size: 24px; font-family: "arial black", "avant garde";">COVID-19</span><span style="font-size: 24px;">和疱疹</span></span></p><p style="line-height: 2em;">诸平</p><p style="line-height: 2em;"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202108/25/160546l5kousn8am8sotnl.jpg" title alt="1001.jpg" referrerpolicy="no-referrer"><br></p><p style="line-height: 2em;"><a href="https://www.acs.org/content/acs/en/pressroom/newsreleases/2021/august/possible-new-antivirals-against-covid-19-herpes.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Peptoids (blue, left) pierce the protective coat of a virus, causing its disintegration and inactivation (right).</span></a><span style="font-size: 18px; font-family: "times new roman";"> Credit: Maxwell Biosciences</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">据美国化学学会（</span><a href="http://portal.acs.org/" target="_blank" style="font-size: 18px; font-family: "times new roman";">American Chemical Society</a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-family: 宋体;">简称</span>ACS<span style="font-family: 宋体;">）</span>2021<span style="font-family: 宋体;">年</span>8<span style="font-family: 宋体;">月</span>24<span style="font-family: 宋体;">日提供的消息，该会</span>2021<span style="font-family: 宋体;">年秋季会议（</span></span><a href="http://www.acs.org/acsfall2021briefings" style="font-size: 18px; font-family: "times new roman";" target="_blank">ACS Fall 2021</a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-family: 宋体;">）上，研究人员在会议上展示他们的结果。</span>ACS2021<span style="font-family: 宋体;">年秋季会议是一场混合会议，于</span>8<span style="font-family: 宋体;">月</span>22-26<span style="font-family: 宋体;">日以虚拟方式和面对面方式举行，在线浏览内容将于</span>8<span style="font-family: 宋体;">月</span>30<span style="font-family: 宋体;">日至</span>9<span style="font-family: 宋体;">月</span>30<span style="font-family: 宋体;">日提供。会议将就广泛的科学主题进行</span>7,000<span style="font-family: 宋体;">多场演讲。“合成肽模拟物：可能针对</span> COVID-19 <span style="font-family: 宋体;">和疱疹的新型抗病毒药物（</span></span><a href="https://scitechdaily.com/synthetic-peptide-mimics-possible-new-antivirals-against-covid-19-and-herpes" style="font-size: 18px; font-family: "times new roman";" target="_blank">Synthetic peptide mimics: Possible new antivirals against COVID-19 and herpes</a><span style="font-size: 18px; font-family: "times new roman";">）</span><span style="font-size: 18px; font-family: 宋体;">就是其中之一。上述来自麦克斯韦生物科学提供的照片，就是类肽类（</span><span style="font-family: "times new roman"; font-size: 18px;">Peptoids</span><span style="font-size: 18px; font-family: 宋体;">）（蓝色，左图）刺穿病毒的保护层，导致其分解和失活（右图）。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">除了抗体和白细胞外，免疫系统还使用肽类（</span>peptides<span style="font-size: 18px; font-family: 宋体;">）来对抗病毒和其他病原体。合成肽类（</span>Synthetic peptides<span style="font-size: 18px; font-family: 宋体;">）可以加强这种防御，但不会在体内持续很长时间，因此研究人员正在开发稳定的肽模拟物（</span>peptide mimics<span style="font-size: 18px; font-family: 宋体;">）。</span>2021<span style="font-size: 18px; font-family: 宋体;">年</span>8<span style="font-size: 18px; font-family: 宋体;">月</span>24<span style="font-size: 18px; font-family: 宋体;">日，科学家在</span>CAS2021<span style="font-size: 18px; font-family: 宋体;">秋季会议上报告了他们成功地使用称为拟肽即类肽类（</span>peptoids<span style="font-size: 18px; font-family: 宋体;">）的模拟物治疗患有疱疹病毒感染动物的实验结果。这些小的合成分子有朝一日可以治愈或预防多种感染，包括</span>COVID-19<span style="font-size: 18px; font-family: 宋体;">。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">该项目的主要研究人员之一、斯坦福大学（</span>Stanford University<span style="font-size: 18px; font-family: 宋体;">）的安纳莉丝·巴伦（</span>Annelise Barron<span style="font-size: 18px; font-family: 宋体;">）博士说：</span>“<span style="font-size: 18px; font-family: 宋体;">在体内，诸如</span>LL-37<span style="font-size: 18px; font-family: 宋体;">之类的抗菌肽（</span></span><a href="https://phys.org/tags/antimicrobial+peptides/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">antimicrobial peptides</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）有助于控制病毒、细菌、真菌、癌细胞甚至寄生虫。</span>”<span style="font-size: 18px; font-family: 宋体;">但是肽类物质会被酶迅速清除，因此它们不是理想的候选药物。相反，安纳莉丝·巴伦和她的同事在称为类肽类（</span>peptoids<span style="font-size: 18px; font-family: 宋体;">）的更小、更稳定的分子中模拟了</span>LL-37<span style="font-size: 18px; font-family: 宋体;">的关键生物物理特性。安纳莉丝·巴伦说：</span>“<span style="font-size: 18px; font-family: 宋体;">类肽类（</span>peptoids<span style="font-size: 18px; font-family: 宋体;">）很容易制造，而且与肽类（</span></span><a href="https://phys.org/tags/peptides/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">peptides</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）不同，它们不会被酶迅速降解，因此它们的使用剂量要低得多。</span>”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">肽类（</span>Peptides<span style="font-size: 18px; font-family: 宋体;">）由氨基酸的短序列组成，侧链与分子骨架中的碳原子相连。这种结构很容易被酶分解。在拟肽（</span>peptoids<span style="font-size: 18px; font-family: 宋体;">）中，侧链与分子骨架中的氮原子相连，形成抵抗酶解的结构。它们最初是由奇隆公司（</span>Chiron Corp.<span style="font-size: 18px; font-family: 宋体;">）的罗纳德·祖克尔曼（</span>Ronald Zuckermann<span style="font-size: 18px; font-family: 宋体;">）博士（后来成为安纳莉丝·巴伦的博士后导师）于</span>1992<span style="font-size: 18px; font-family: 宋体;">年创建的。与其他类型的肽模拟物（</span>peptide mimics<span style="font-size: 18px; font-family: 宋体;">）不同，它们需要费力的、多步骤的有机化学来生产；使用自动合成仪和现成的化学品制造拟肽（</span>peptoids<span style="font-size: 18px; font-family: 宋体;">）既简单又便宜。安纳莉丝·巴伦说：</span>“<span style="font-size: 18px; font-family: 宋体;">制作拟肽（</span>peptoids<span style="font-size: 18px; font-family: 宋体;">）类化合物几乎就像在面包机中制作面包一样轻而易举。</span>”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体; color: blue;">美国</span><span style="font-size: 18px; font-family: 宋体;">路易斯维尔大学（</span>University of Louisville<span style="font-size: 18px; font-family: 宋体;">）的安纳莉丝·巴伦、罗纳德·祖克尔曼、吉尔·戴蒙德（</span>Gill Diamond<span style="font-size: 18px; font-family: 宋体;">）博士和其他人创立了麦斯威尔生物科学公司（</span>Maxwell Biosciences<span style="font-size: 18px; font-family: 宋体;">），以开发拟肽（</span>peptoids<span style="font-size: 18px; font-family: 宋体;">）作为临床候选物来预防或治疗病毒感染。他们最近报告了他们最新的拟肽序列的结果，这些序列被设计为比以前的版本对人的毒性更小。在实验室培养皿中，这些化合物灭活了导致</span> COVID-19 <span style="font-size: 18px; font-family: 宋体;">的</span>SARS-CoV-2<span style="font-size: 18px; font-family: 宋体;">和导致口腔唇疱疹的单纯疱疹病毒</span> 1 (herpes simplex virus-1<span style="font-size: 18px; font-family: 宋体;">简称</span>HSV-1)<span style="font-size: 18px; font-family: 宋体;">，使病毒无法感染培养的人类细胞（</span></span><a href="https://phys.org/tags/human+cells/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">human cells</span></a><span style="font-size: 18px; font-family: "times new roman";">）。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">现在，研究人员正在报告体内结果，表明当将拟肽轻轻地敷在小鼠的嘴唇时，则可以安全地预防小鼠的疱疹感染。吉尔·戴蒙德的团队正在进行额外的实验以确认在小鼠身上的发现。此外，他们将研究拟肽对抗阿昔洛韦（</span>acyclovir<span style="font-size: 18px; font-family: 宋体;">）的</span> HSV-1 <span style="font-size: 18px; font-family: 宋体;">菌株的有效性，阿昔洛韦是目前美国食品和药物管理局（</span>FDA<span style="font-size: 18px; font-family: 宋体;">）批准的针对疱疹感染情况的最佳抗病毒治疗药物，安纳莉丝·巴伦说。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">研究人员还准备在小鼠中测试拟肽对</span>SARS-CoV-2<span style="font-size: 18px; font-family: 宋体;">的活性。安纳莉丝·巴伦说：</span>“COVID-19 <span style="font-size: 18px; font-family: 宋体;">感染涉及整个身体，一旦有人真的生病了，我们将通过静脉注射进行这项测试，并观察向肺部的输送情况。</span>”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">但是这些抗菌分子（</span>antimicrobial molecules<span style="font-size: 18px; font-family: 宋体;">）可能有更多的应用。斯坦福大学正在进行研究，以探索它们对耳部和肺部感染的影响。安纳莉丝·巴伦已将拟肽样本发送给其他实验室的专家，以测试一系列病毒，在针对流感、感冒病毒以及乙型和丙型肝炎的实验室培养皿研究中取得了令人鼓舞的结果。</span>“<span style="font-size: 18px; font-family: 宋体;">在他们的体外研究中，一个团队发现其中两种拟肽是迄今为止针对中东呼吸综合征（</span>Middle East respiratory syndrome<span style="font-size: 18px; font-family: 宋体;">简称</span>MERS<span style="font-size: 18px; font-family: 宋体;">）和较早的</span> SARS <span style="font-size: 18px; font-family: 宋体;">冠状病毒鉴定出的最有效的抗病毒药物，</span>”<span style="font-size: 18px; font-family: 宋体;">安纳莉丝·巴伦说。其他实验室正在测试拟肽作为气道和肠道的抗真菌剂以及隐形眼镜（</span>contact lenses<span style="font-size: 18px; font-family: 宋体;">）、导管（</span>catheters<span style="font-size: 18px; font-family: 宋体;">）和植入的髋关节和膝关节（</span>implanted hip and knee joints<span style="font-size: 18px; font-family: 宋体;">）的抗感染涂层。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">吉尔·戴蒙德和安纳莉丝·巴伦正在研究这些广谱化合物的工作原理。它们似乎刺穿并破坏病毒包膜，并与病毒的</span>RNA<span style="font-size: 18px; font-family: 宋体;">或</span>DNA <span style="font-size: 18px; font-family: 宋体;">结合。安纳莉丝·巴伦说，这种多管齐下的机制具有灭活病毒的优势，这与标准抗病毒药物不同，后者会减慢病毒复制但仍允许病毒感染细胞。它还降低了病原体产生耐药性的可能性。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">安纳莉丝·巴伦预计临床试验将在年内开始。她说，如果成功，可以使用拟肽作为预防措施</span>——<span style="font-size: 18px; font-family: 宋体;">例如，在航空旅行之前保护乘客免受</span> COVID-19 <span style="font-size: 18px; font-family: 宋体;">的侵害</span>——<span style="font-size: 18px; font-family: 宋体;">或者在感染发生之后，例如当一个人感到即将到来的唇疱疹的刺痛感时。</span><br></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">病毒感染，例如由单纯疱疹病毒</span>1 (Herpes Simplex Virus-1<span style="font-size: 18px; font-family: 宋体;">简称</span>HSV-1) <span style="font-size: 18px; font-family: 宋体;">和</span> SARS-CoV-2 <span style="font-size: 18px; font-family: 宋体;">引起的感染，每年影响数百万人。然而，能有效治疗这些感染的抗病毒药物很少。开发抗病毒药物的标准方法包括识别独特的病毒靶标，然后设计针对该靶标的药剂。抗菌肽</span> (Antimicrobial peptides <span style="font-size: 18px; font-family: 宋体;">简称</span>AMP) <span style="font-size: 18px; font-family: 宋体;">是潜在抗病毒药物的新来源。已显示</span>AMP<span style="font-size: 18px; font-family: 宋体;">通过破坏病毒包膜使许多不同的包膜病毒失活。然而，</span>AMPs<span style="font-size: 18px; font-family: 宋体;">作为抗菌疗法的临床开发受到许多因素的阻碍，特别是它们作为肽类物质的酶不稳定结构。安纳莉丝·巴伦等人他们已经检查了</span>AMPs<span style="font-size: 18px; font-family: 宋体;">（</span>sequence-specific N-substituted glycine oligomers<span style="font-size: 18px; font-family: 宋体;">）的拟肽模拟物的抗病毒潜力。这些拟肽具有对蛋白酶不敏感的独特优势，并且还表现出更高的生物利用度和稳定性。研究结果表明，在感染前孵育时，几种拟肽对</span>HSV-1<span style="font-size: 18px; font-family: 宋体;">和</span>SARS-CoV-2<span style="font-size: 18px; font-family: 宋体;">均表现出有效的体外抗病毒活性。换句话说，它们对病毒结构有直接影响，这似乎使病毒颗粒具有非感染性。冷冻电镜可视化显示病毒包膜破坏类似于</span>AMPs<span style="font-size: 18px; font-family: 宋体;">对其他病毒的活性所观察到的破坏。此外，研究者没有观察到对口腔上皮细胞原代培养物的细胞毒性。这些结果表明了一个共同的或仿生的机制，可能是由于病毒包膜和宿主细胞膜的磷脂头基（</span>phospholipid head group<span style="font-size: 18px; font-family: 宋体;">）组成之间的差异，因此强调了这类分子作为安全有效的广谱抗病毒药物的潜力。研究者讨论了</span>10<span style="font-size: 18px; font-family: 宋体;">种拟肽候选物之间不同的分子特征如何以及为什么会影响抗病毒活性和选择性。最后，讨论了有希望的新结果，表明对鼻病毒和乙型肝炎病毒具有抗病毒肽活性。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">此研究得到了美国国立卫生研究院、麦斯威尔生物科学公司（</span>Maxwell Biosciences<span style="font-size: 18px; font-family: 宋体;">）的资助。上述介绍，仅供参考。欲了解更多信息，敬请注意浏览</span></span><a href="http://www.acs.org/acsfall2021briefings" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">原文</span></a><span style="font-size: 18px; font-family: "times new roman";">或者</span><a href="https://www.acs.org/content/acs/en/pressroom/newsreleases/2021/august/possible-new-antivirals-against-covid-19-herpes.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">相关报道</span></a><span style="font-size: 18px; font-family: "times new roman";">。</span></p><p style="line-height: 2em;"><a href="https://scitechdaily.com/synthetic-peptide-mimics-possible-new-antivirals-against-covid-19-and-herpes/" style="text-decoration: underline; font-size: 18px; font-family: "arial black", "avant garde";" target="_blank"><span style="font-size: 18px; font-family: "arial black", "avant garde";">Potent antiviral activity against HSV-1 and SARS-CoV-2 by antimicrobial peptoids</span></a></p><p style="line-height: 2em;"><a href="https://scitechdaily.com/synthetic-peptide-mimics-possible-new-antivirals-against-covid-19-and-herpes/" style="text-decoration: underline; font-size: 18px; font-family: "arial black", "avant garde";" target="_blank"><span style="font-size: 18px; font-family: "arial black", "avant garde";">Abstract</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Viral infections, such as those caused by Herpes Simplex Virus-1 (HSV-1) and SARS-CoV-2, affect millions of people each year. However, there are few antiviral drugs that can effectively treat these infections. The standard approach in the development of antiviral drugs involves the identification of a unique viral target, followed by the design of an agent that addresses that target. Antimicrobial peptides (AMPs) represent a novel source of potential antiviral drugs. AMPs have been shown to inactivate numerous different enveloped viruses through the disruption of their viral envelopes. However, the clinical development of AMPs as antimicrobial therapeutics has been hampered by a number of factors, especially their enzymatically labile structure as peptides. We have examined the antiviral potential of peptoid mimics of AMPs (sequence-specific N-substituted glycine oligomers). These peptoids have the distinct advantage of being insensitive to proteases, and also exhibit increased bioavailability and stability. Our results demonstrate that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2 when incubated prior to infection. In other words, they have a direct effect on the viral structure, which appears to render the viral particles non-infective. Visualization by cryo-EM shows viral envelope disruption similar to what has been observed with AMP activity against other viruses. Furthermore, we observed no cytotoxicity against primary cultures of oral epithelial cells. These results suggest a common or biomimetic mechanism, possibly due to the differences between the phospholipid head group makeup of viral envelopes and host cell membranes, thus underscoring the potential of this class of molecules as safe and effective broad-spectrum antiviral agents. We discuss how and why differing molecular features between 10 peptoid candidates may affect both antiviral activity and selectivity. Finally, we will discuss promising new results indicating antiviral peptoid activity against Rhinovirus and Hepatitis B virus.</span></p><p><br></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-212210-1301398.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-212210-1301398.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1301282.html" target="_black">非编码RNA在衰老和癌症中的新功能</a><br>下一篇：<a href="http://blog.sciencenet.cn/blog-212210-1301492.html" target="_black">一名学生的使命:保护世界上最珍贵的资源</a>                    <!--大赛结束-->
                                        
  
</div>
            